What is the efficacy of certolizumab in the treatment of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print
Answer

In the PRECISE (Pegylated Antibody Fragment Evaluation in Crohn’s Disease: Safety and Efficacy) trials, certolizumab pegol, a humanized Fab’ antibody fragment conjugated to polyethylene glycol, demonstrated efficacy in maintaining remission in patients with moderately to severely active Crohn disease.

In PRECISE 1, certolizumab yielded greater clinical response (37%) in patients with high CRP levels (≥ 10 mg/L) at week 6 than placebo (26%), as well as greater persistence of response at 6 months (22% vs 12%, respectively). [105] Remission rates did not differ between treatment and placebo groups. In PRECISE 2, when week 6 responders were randomized to drug or placebo, certolizumab yielded clinical remission in 36% and clinical response in 63%. [106] In PRECISE 3, 41% of patients achieved remission at 12 months and 36% at 18 months. [107]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!